The opioid receptor like-1 receptor agonist Ro 64-6198 (1S, 3aS-8-2, 3, 3a, 4, 5, 6-hexahydro-1H-phenalen-1-yl-1-phenyl-1, 3, 8-triaza-spiro [4.5] decan-4-one) …
MD Recker, GA Higgins - Journal of Pharmacology and Experimental …, 2004 - ASPET
Male Wistar rats were trained to discriminate either the opioid receptor like (ORL)-1 receptor
agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-…
agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-…
Safety of bisphosphonates in the treatment of osteoporosis
RR Recker, EM Lewiecki, PD Miller, J Reiffel - The American journal of …, 2009 - Elsevier
In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy
for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to …
for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to …
[HTML][HTML] Prostate-cancer mortality at 11 years of follow-up
Background Several trials evaluating the effect of prostate-specific antigen (PSA) testing on
prostate-cancer mortality have shown conflicting results. We updated prostate-cancer …
prostate-cancer mortality have shown conflicting results. We updated prostate-cancer …
The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma
F Recker, MK Kwiatkowski, T Piironen… - … Journal of the …, 1998 - Wiley Online Library
The importance of human glandular kallikrein and its correlation with different prostate
specific antigen serum forms in the detection of prostate carcinoma - Recker - 1998 - Cancer - …
specific antigen serum forms in the detection of prostate carcinoma - Recker - 1998 - Cancer - …
[HTML][HTML] Screening and prostate-cancer mortality in a randomized European study
Background The European Randomized Study of Screening for Prostate Cancer was
initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen (PSA) …
initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen (PSA) …
[HTML][HTML] Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
…, M Favus, E Seeman, RR Recker… - … England Journal of …, 1995 - Mass Medical Soc
… Recker, MD, … Hirsch, MD, … Karpf, MD …
[PDF][PDF] The ORL-1 receptor agonist, Ro 64-6198, produces a discriminative stimulus in rats distinct from that of a mu, kappa and delta opioid receptor agonist cue
MD Recker, GA Higgins - Journal of Pharmacology and …, 2004 - researchgate.net
Male wistar rats were trained to discriminate either the ORL-1 receptor agonist Ro 64-6198
or morphine, from saline, using a two-choice, food reinforced, operant procedure. Acquisition …
or morphine, from saline, using a two-choice, food reinforced, operant procedure. Acquisition …
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
OBJECTIVE: An effective and well tolerated intravenous (IV) bisphosphonate could provide
a new treatment method for patients with osteoporosis. The Dosing IntraVenous …
a new treatment method for patients with osteoporosis. The Dosing IntraVenous …
The COX‐2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial
PT Leese, DP Recker, JD Kent - The Journal of Clinical …, 2003 - Wiley Online Library
The effects of the new cyclooxygenase (COX)‐2 selective inhibitor, valdecoxib (40 mg bid; n
= 17), on platelet function were evaluated, along with ibuprofen (800 mg tid; n = 15) and …
= 17), on platelet function were evaluated, along with ibuprofen (800 mg tid; n = 15) and …
[PDF][PDF] High bone density due to a mutation in LDL-receptor-related protein 5
To the Editor: Boyden et al.(May 16 issue) 1 describe a kindred with high bone density due
to a mutation in the gene for low-density lipoprotein (LDL) receptor–related protein 5 (LRP5). …
to a mutation in the gene for low-density lipoprotein (LDL) receptor–related protein 5 (LRP5). …